ANIP's Business Model
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Sector & Industry | Healthcare / Drug Manufacturers - Specialty & Generic |
Website | https://www.anipharmaceuticals.com |
CEO (Chief Executive Officer) | Nikhil Lalwani |
Number of Employees | |
IPO date | May 5, 2000 |
ANIP Latest News
|
|
|
|
|
Contact | |
---|---|
Country | US |
Address | 210 Main Street West |
City | Baudette |
State | MN |
Phone | 218 634 3500 |
Zip Code | 56623 |
Other Identifiers | |
CIK | 0001023024 |
ISIN | US00182C1036 |
CUSIP | 00182C103 |
Open | 65.2 |
Previous Close | 65.22 |
Volume | 98.5 Thou. |
Average Volume | 368 Thou. |
Day’s Range | 63.74 – 65.72 |
52 Week Range | 52.5-77 |
MA (50) | 64.2942 |
MA (200) | 60.69395 |
Market Cap | 1.41 Bil. |
Shares Out. | 21.65 Mil. |
Earnings Date | Aug 04, 2025 |
Beta | |
Last Dividend | |
EPS | |
PE | |